A comprehensive summary of the FDA Form 483 issued to Aurobindo Pharma Limited,

Unit VII (Inspection dated Jan 28 – Feb 10 2026), including what went wrong at the quality system level — root causes, system failures, and broader quality-management insights such as internal audit and management review failures, and cognitive biases like the Dunning-Kruger Effect — to help you contextualize the findings

🔸 Facility and Equipment Systems – Cleaning & Contamination Control:
Equipment and utensils were not cleaned at appropriate intervals, some never cleaned since installation.
HEPA filters and ducts contained layered dust and bird droppings, indicating potential microbial contamination and cross-contamination risk.
Preventive maintenance procedures lacked oversight by the Quality Unit, leading to unidentified risk and no investigation of potential impacts.
🔸 Production and Computer Controls:
Multiple undocumented empty trial runs.
Computers used shared credentials, deletion permissions, and back-dating — creating data integrity gaps.
🔸 Master Production & Control Records:
Batch records lacked key instructions and fields, such as stratified sampling times and limits for critical variables.
Operators relied on visual judgment without defined process controls.
🔸 Complaint Handling System Deficiencies:
Complaint investigations were incomplete, with ~41 % missing essential findings and follow-up analysis.
No shipment or drop-test studies, and insufficient risk analysis for packaging complaints.
🔸 Failure to Investigate Unexplained Discrepancies:
Quality Unit lacked adequate review of discrepancies and out-of-specification conditions, including stability issues and impurity trends.
Batches at risk for impurity or stability failures were kept on market without adequate actions.
🔸 Quality Control Unit Responsibilities Not Adequate:
QC unit procedures were incomplete or not fully followed, including microbiology sampling practices that lacked fundamental integrity.
No investigations, risk assessments, or CAPAs initiated in response to observed deficiencies.
🔸 Inadequate GMP Training Program:
Training was not conducted with sufficient frequency or completeness to ensure familiarity with CGMP.
Large percentages of staff had overdue or incomplete training documentation.
🔸 Laboratory Control System Record-Keeping Deficiencies:
Laboratory records lacked complete documentation; signatures were dated incorrectly and did not reflect actual test dates.
Raw data capture and reporting were inconsistent.
🔸 Additional Data Integrity & Laboratory Controls Issues:
Although the public document’s later pages are redacted, the pattern of findings strongly indicates continued lab record deficiencies, lack of raw data recording, and poor data review for critical quality tests (e.g., incomplete date documentation, absent or overwritten analytical reports).